[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590506":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":32,"responsibleParty":50,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":19,"enrollmentInfo":62,"targetDuration":19,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":35,"whyStopped":19,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"SunWay Biotech Co., LTD.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules","EXPERIMENTAL","ExoBDNF is the product name of SWP-CGPA01 Pediococcus acidilactici, which is listed as a food-usable strain in Taiwan, China, Europe and the United States. The strain has been deposited in the National Collection of Industrial Food and Marine Bacteria (NCIMB) in the United Kingdom, and the strain number is NCIMB 44102. 1.0 x 1010 CFU SWP-CGPA01 freeze-dried powder (production and development: Morning Blossom Biotechnology Co., Ltd., Taipei, Taiwan), corn starch, crystalline cellulose and excipients in plant capsules.",[13],"Dietary Supplement: ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DIETARY_SUPPLEMENT","Product ingredients: microcrystalline cellulose, corn starch, SWP-CGPA01 Pediococcus acidilactici powder (1.0 x 10\\^10 CFU); Capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gelatin.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Hsin-An Chang, MD","Director, Child and Adolescent Psychiatry, Department of Psychiatry","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Sean Lin","CONTACT","02-27929568","612","sean.lin@sunway.cc",[33],{"facility":34,"status":35,"city":36,"state":19,"zip":19,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Tri-Service General Hospital, National Defense Medical Center","RECRUITING","Taipei","Taiwan","TW",{"type":40,"coordinates":41},"Point",[42,43],121.52639,25.05306,{"lat":43,"lon":42},[46,49],{"name":47,"role":28,"phone":48,"phoneExt":19,"email":19},"Ellie LAI, master","0287924955",{"name":22,"role":24,"phone":19,"phoneExt":19,"email":19},{"type":51,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100590506","effect-of-exobdnf-lactic-acid-bacteria-supplement-on-cognitive-functions-sleep-and-psychological-100590506",false,"NCT06968299","Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological","Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological Outcomes: An Open-label Trial","Inclusion Criteria:\n\n1. Subjects must be volunteers who are 18 years of age or older, mentally clear and able to communicate.\n2. Subjects who agree to participate in this trial and voluntarily sign the trial consent form.\n\nExclusion Criteria:\n\n1. Subjects who are expected to be or have been confirmed to be pregnant (medical history).\n2. Subjects with gallbladder disease, gastrointestinal disease, gout, porphyria, or a history of gastric weight control surgery.\n3. Subjects with high blood pressure (≥160\u002F100 mmHg after resting for 10 minutes) or taking diuretics.\n4. Subjects with heart disease, hepatorenal insufficiency, hyperthyroidism or hypothyroidism, Cushing's syndrome, malignant tumors, or any other disease that may affect the results of the study.\n5. Subjects with severe hearing or visual impairment that makes it impossible to perform examinations and assessments.\n6. Subjects with any history of brain surgery, penetrating, neurovascular, infectious or other severe brain injury, epilepsy or other major neurological abnormalities, such as traumatic brain injury with loss of consciousness for more than 24 hours, or memory loss after head trauma for more than 7 days were excluded.\n7. Subjects with intellectual disabilities.\n8. Subjects who had consumed probiotics or were expected to consume probiotics within 2 weeks before the screening visit.\n9. Subjects who had participated in or were expected to participate in clinical trials within 4 weeks before the screening visit.",true,"ALL","18 Years",{"count":63,"type":64},50,"ESTIMATED","INTERVENTIONAL",[67],"NA","This open-label, single-group, pre\u002Fpost-test clinical study was conducted to investigate whether ExoBDNF probiotic supplementation could improve cognitive ability. It is expected that 40 subjects aged 18 years and above will be recruited, with a target of 30 cases, to take ExoBDNF probiotics for a total of 8 weeks.",[70,71,72,73],"Cognitive Functions Perceptual Disturbances","Cognitive Function Abnormal","Sleep","Psychological",[75,76,77],"Probiotics","ExoBDNF","Cognitive functions","2025-11-18",{"date":80,"type":81},"2025-11-24","ACTUAL",{"date":83,"type":81},"2025-05-20",{"date":85,"type":64},"2025-12-30",{"name":5,"class":6},1]